Imiquimod Patent Expiration

1. Aldara patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7696159 BAUSCH Treatment for basal cell carcinoma
Apr, 2024

(3 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159

(Pediatric)

BAUSCH Treatment for basal cell carcinoma
Oct, 2024

(2 months from now)




Market Authorisation Date: 27 February, 1997

Treatment: Works through the induction of interferon and other cytokines

Dosage: CREAM

How can I launch a generic of ALDARA before it's drug patent expiration?
More Information on Dosage

ALDARA family patents

Family Patents

2. Zyclara patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238645 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Aug, 2029

(5 years from now)

US8598196 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
Aug, 2029

(5 years from now)

US8236816 BAUSCH 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod
Dec, 2029

(5 years from now)

US8222270 BAUSCH 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod
Dec, 2029

(5 years from now)

US11318130 BAUSCH 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
Dec, 2029

(5 years from now)

US10238644 BAUSCH 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
Dec, 2029

(5 years from now)

US8299109 BAUSCH Method of treating actinic keratosis with 3.75% imiquimod cream
Dec, 2029

(5 years from now)

US11850245 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Apr, 2030

(5 years from now)

US11202752 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
Apr, 2030

(5 years from now)

US10918635 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Apr, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 25, 2013
New Indication(I-636) Mar 24, 2014
New Strength(NS) Jul 15, 2014

Market Authorisation Date: 15 July, 2011

Treatment: Treatment of perianal warts; Treatment of actinic keratosis; Treatment of genital warts

Dosage: CREAM

How can I launch a generic of ZYCLARA before it's drug patent expiration?
More Information on Dosage

ZYCLARA family patents

Family Patents